Nasdaq

Disc Medicine, Inc. Outlines Clinical Development Plans and Milestones for 2025, Highlighting Potential Accelerated Approval for Bitopertin

Disc Medicine, Inc. announced its plans for 2025, highlighting key developments in its clinical programs focused on hematologic diseases. The company will discuss plans for NDA submission of ...
Nasdaq

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

WATERTOWN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Insider Monkey

Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025

We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Disc Medicine, Inc. stands sixth on our list and nears FDA filing for the first-ever EPP treatment. Disc ...